Project Grant R01HL179184
Award Date 7/15/26
Completion Date 3/31/30
Dollars Obligated $754K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40208, USA
Similar Awards
- Federal Project Grant Award Summary The University of Arizona received a $1.34 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with a completion date of June 30, 2029. The award funds basic research investigating the role of hexokinase 3 (HK3) in macrophage polarization and cardiac remodeling following myocardial infarction and ischemia/reperfusion injury. The research...
- Federal Project Grant Award Summary The University of Arizona received a $650,419 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2026, with completion targeted for March 31, 2030. The award funds research to develop a comprehensive mechanistic understanding of sarcomeric protein interactions and their role in hypertrophic cardiomyopathy (HCM). The research extends the investigator's...
- Federal Project Grant Award Summary The University of Arizona received a $562,733 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 6, 2026, with completion targeted for May 31, 2027. The award funds research to develop small molecule therapeutics for heart failure by inhibiting tristetraprolin (TTP), a protein that regulates cardiac metabolism and inflammatory responses. The research...
- Federal Grant Award Summary The University of Arizona received a Project Grant award of $558,127 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2026, with a completion date of July 31, 2033. This multidisciplinary research initiative, titled "Decoding the Enigma of Cardiac Arrhythmia and Mechanosensitivity," aims to elucidate the role of small conductance calcium-activated potassium (SK)...
- Federal Grant Award Summary The University of Arizona received a $1,447,654 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through May 31, 2029. The award funds research on "Selective Targeting of Alveolar Capillaries in Neonatal Lung Injury," addressing a critical therapeutic gap in treating bronchopulmonary dysplasia with pulmonary hypertension (BPD-PH), a severe...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Arizona a Project Grant of $743,545 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period July 15, 2026, through March 31, 2030. The project focuses on applying deep learning computational methods to identify selective small-conductance calcium-activated potassium (SK) channel inhibitors for atrial fibrillation treatment. Atrial fibrillation represents a major...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Arizona a $1.57M Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective June 5, 2026, through February 29, 2028, to investigate ATF6 as a regulator of atrial myocyte endoplasmic reticulum (ER) proteostasis. The research focuses on understanding how the transcription factor ATF6 maintains protein homeostasis in atrial myocytes, particularly as it relates to the...
- Grant Award Summary The University of Arizona received a $576,786 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion targeted for August 31, 2028. This research initiative investigates protein translation mechanisms underlying oxidative stress response in heart failure, specifically examining the role of YTHD2 (a YTH domain-containing N6-methyladenosine binding...
- Federal Project Grant Award Summary The University of Arizona received a $577,065 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2026, with a completion date of May 31, 2031. This research award supports investigation into the roles of endoplasmic reticulum (ER) stress in calcium-dependent cardiac arrhythmias, with particular focus on the ryanodine receptor (RYR2) dysfunction...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $1,254,849 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research aimed at improving cardiac microenvironment treatment strategies for diabetic ischemic heart failure (IHF). The project, scheduled for completion by June 30, 2029, focuses on developing engineered approaches to modify small extracellular...